SCHEMBL6282486

SCHEMBL6282486

COc1ccc(-c2nc(NC(=O)Nc3ccccc3)sc2-c2ccncc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.67
MEN1 O00255 8/20 0.67
KMT2A Q03164 8/20 0.67
ALDH1A1 P00352 4/20 0.67
KDM4E B2RXH2 4/20 0.62
LMNA P02545 3/20 0.62
GAA P10253 1/20 0.62
RAB9A P51151 3/20 0.59
POLB P06746 2/20 0.59
MAPK1 P28482 1/20 0.59
HTT P42858 1/20 0.59
USP2 O75604 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
PTGS2 P35354 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.55
NPC1 O15118 2/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6545476 0.86 MAPT (0.74) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6281996 0.84 MAPT (0.62) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6546546 0.84 MAPT (0.88) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6285228 0.83 MAPT (0.63) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6278906 0.83 ADORA3 (0.64) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL6282347 0.82 MAPT (0.69) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6546415 0.82 MAPT (0.61) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6280826 0.81 MAPT (0.66) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6545612 0.81 MAPT (0.66) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6546252 0.81 MAPT (0.66) MAPTMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1205478-A1 p38MAP KINASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2002-05-15 EP claimed
US-6962933-B1 Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-11-08 US disclosed
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed
US-20040097555-A1 Concomitant drugs TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-20 US disclosed
EP-1402900-A1 MEDICINAL COMPOSITIONS Takeda Chemical Industries, Ltd. (JP) 2004-03-31 EP disclosed
EP-1354603-A1 CONCOMITANT DRUGS Takeda Chemical Industries, Ltd. (JP) 2003-10-22 EP disclosed
EP-1205478-A1 p38MAP KINASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2002-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 MAPT 2844/4885MEN1 4508/4885KMT2A 4107/4885
US-20040097555-A1 Concomitant drugs TNF, CHUK, CNKSR1 MAPT 2113/4885MEN1 3920/4885KMT2A 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.